Why Krystal Biotech (KRYS) Is Drawing Fresh Attention

Krystal Biotech (KRYS) is drawing fresh attention after news that its VYJUVEK gene therapy for dystrophic epidermolysis bullosa has gained commercial traction, supported by high revenue, strong gross margins, and recurring treatment demand. Recent trading shows a mixed picture for Krystal Biotech. The share price has eased about 9% over the past month and roughly 13% over the last quarter, yet the year-to-date share price return of 31.45% and 1-year total shareholder return of 73.40% point to...